Ads
related to: astrazeneca stock- Trade
Buy, sell, track the market.
Discover our investment products.
- Ranked #1 in Research
Kiplinger's Best Online Brokers
Annual Review from August 31, 2023
- Open an Account
Choose The Account That Works
Best For You, and Start Investing
- Learn How To Trade
We can help you invest with speed
& accuracy at every step of a trade
- Trade
Search results
3 No-Brainer Stocks to Buy in June
Motley Fool via Yahoo Finance· 6 days agoTrading at 18 times its expected future earnings, the stock's valuation is attractive when compared to the average healthcare stock, which trades at a...
Deutsche Bank maintains 'Hold' on AstraZeneca post ASCO conference By Investing.com
Investing.com· 3 days agoOn Monday, Deutsche Bank (ETR:DBKGn) reiterated a Hold rating and a price target of GBP110.00 on ...
AstraZeneca Buy rating, stock target reiterated on consistent presence By Investing.com
Investing.com· 3 days agoOn Wednesday, Citi reaffirmed its Buy rating on AstraZeneca (NASDAQ:AZN) shares with a steady price...
Astrazeneca (AZN) Beats Stock Market Upswing: What Investors Need to Know
Zacks via Yahoo Finance· 4 days agoIt is also important to note the recent changes to analyst estimates for Astrazeneca. Recent...
First Trust Advisors LP Raises Stock Position in AstraZeneca PLC (NASDAQ:AZN)
ETF DAILY NEWS· 2 days agoThe institutional investor owned 1,390,959 shares of the company’s stock after buying an additional 95,652 shares during the period. First Trust Advisors LP’s holdings in ...
AstraZeneca completes acquisition of biopharma company Fusion Pharma
dpa international via Yahoo Finance· 3 days agoBritish pharmaceutical company AstraZeneca on Wednesday announced the completion of the acquisition...
Pharma Stock Roundup: LLY's CFO Departs, ABBV, AZN Drugs Get CHMP Approval
Zacks via Yahoo Finance· 18 hours agoThe CHMP also recommended the expanded use of AstraZeneca’s Tagrisso plus chemotherapy for...
AbbVie's (ABBV) Ovarian Cancer Therapy Meets Study Goal
Zacks via Yahoo Finance· 18 hours agoData from a mid-stage study shows that treatment with AbbVie's (ABBV) Elahere achieves an objective...
Summit Therapeutics, AstraZeneca And More From The Year’s Biggest Cancer Conference
Forbes· 2 days agoThe conference was a big one for Summit Therapeutics, which saw its stock price more than double...
The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy.
Motley Fool via Yahoo Finance· 5 days agoData from the phase 2 study is due later this year. Expect the stock to get a healthy bump if the...